Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Maintenance therapy in MM: perspectives

Graham Jackson • 6 Dec 2019
ASH 2019
Multiple Myeloma Antibodies Bortezomib Daratumumab Ixazomib Lenalidomide

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK, outlines the perspectives on maintenance therapy in multiple myeloma (MM). Prof. Jackson highlights the use of lenalidomide, daratumumab and ixazomib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Graham Jackson

Myeloma treatment updates: a UK perspective
Graham Jackson et al. • 14 Jun 2022
The management of patients with lenalidomide-refractory multiple myeloma in the UK 1:00
The management of patients with lenalidomide-refractory multiple myeloma in the UK
Graham Jackson • 30 Jan 2025
Recent approvals and updates impacting myeloma treatment in the UK 1:45
Recent approvals and updates impacting myeloma treatment in the UK
Graham Jackson • 30 Jan 2025
Unmet needs that remain for patients with myeloma in the UK 1:19
Unmet needs that remain for patients with myeloma in the UK
Graham Jackson • 30 Jan 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals